Skip to content
Home/Companies/Biotech/BiOligo Biotechnology
BiOligo Biotechnology

BiOligo Biotechnology

Biotech·US·Active
Entry
–
Hold
–
Status
Active

Who owns BiOligo Biotechnology?

BiOligo Biotechnology is currently owned by The Carlyle Group.

Hand-verified · updated 2026-04-21

The Carlyle Group
Investor
The Carlyle Group
Fund attribution unclassified.

Key facts

HQUSA
SectorBiotech
Websiteen.bioligo.com

More from The Carlyle Group Portfolio

Other portfolio companies in the same fund.

Adicon Holdings Limited
Active
MedTechUS
AGILOX Systems GmbH
AGILOX Systems GmbH
Active
LogisticsGermany
Alamar Foods
Alamar Foods
Exited 2022
HospitalitySaudi Arabia
Ampere Computing Holdings LLC
Ampere Computing Holdings LLC
Active
TMTUS
Ant Financial
Active
FintechChina
China Literature Limited
Exited 2017
TMTChina

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Antiverse
Antiverse
Active
Future Planet CapitalUK
Track BiOligo Biotechnology

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy BiOligo Biotechnology?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on BiOligo Biotechnology.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue